Concepedia

David Siegel

DS

Statistics

Publications

11

Citations

717

H-Index

11

Active since

1998

Affiliations

Hackensack University Medical Center(Current)

Emory University

The University of Texas MD Anderson Cancer Center

Washington University in St. Louis

Dana-Farber Cancer Institute

David Siegel is an author at Hackensack University Medical Center specializing in medicine, multiple myeloma therapy, and multiple myeloma.

Publications per year

1998–2022

11

Publications

11

Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies

David Siegel, Thomas G Martin, A. Nooka et al. · Haematologica · 2013 · 344 citations · Full text

, , +11

Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma

James R. Berenson, Sundar Jagannath, Bart Barlogie et al. · Cancer · 2005 · 103 citations

, , +14

A Randomized Trial of Lenalidomide Plus High-Dose Dexamethasone (RD) Versus Lenalidomide Plus Low-Dose Dexamethasone (Rd) in Newly Diagnosed Multiple Myeloma (E4A03): A Trial Coordinated by the Eastern Cooperative Oncology Group.

S. Vincent Rajkumar, Susanna Jacobus, Natalie S. Callander et al. · Blood · 2007 · 76 citations

, , +12

Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients

Maurizio Zangari, Monette Aujay, Fenghuang Zhan et al. · European Journal Of Haematology · 2011 · 44 citations · Full text

, , +16

Clinical and laboratory evaluation of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma

Michèle L. Donato, Steven Park, Melissa Baker et al. · JCI Insight · 2021 · 38 citations · Full text

, , +15

1–5 of 11